Target intelligence / Profile preview

COP9 signalosome complex subunit 1 (GPS1)

Target
GPS1
Molecular classification
Other, Signalosome complex subunit, Regulator of ubiquitin ligase
01

Overview

COP9 signalosome complex subunit 1 (GPS1) is a core component of the COP9 signalosome, a conserved multi-subunit protein complex involved in the regulation of protein degradation via the ubiquitin-proteasome system. It suppresses G-protein and mitogen-activated signal transduction in mammalian cells and participates in the deneddylation of cullin subunits of E3 ubiquitin ligase complexes, modulating their activity and affecting numerous cellular functions including cell cycle, DNA repair, and stress signaling. GPS1 also influences transcription factor stability (such as p53 and c-Jun) through its control over phosphorylation and ubiquitination states. Mutations or dysregulation of GPS1 are implicated in certain cancers and neurological conditions, highlighting its importance as a pivotal regulator of key signaling and proteostasis pathways[1][2][3]. **Notes on evidence:** - GPS1 is not considered a classic therapeutic target (like an enzyme or receptor), but rather a central regulator within a multi-protein complex[1][2]. - No approved drugs directly modulate GPS1 itself; structural/functional roles and risk of broad pleiotropy likely limit its tractability[1][2][3]. - It is essential in a range of physiological processes and can impact disease when mutated but is not presently linked to clinical biomarkers or drug mechanisms[1][2].

Other names
G protein pathway suppressor 1COPS1CSN1SGN1Signalosome subunit 1GPS-1JAB1-containing signalosome subunit 1Protein MFHCOP9 signalosome subunit 1
02

Biological functions

Suppression of G-protein-mediated signal transductionSuppression of mitogen-activated protein kinase (MAPK) signalingComponent of COP9 signalosome regulating ubiquitin conjugation pathwayMediates deneddylation of cullin subunits in E3 ubiquitin ligase complexesRegulation of phosphorylation of key transcription factors (e.g., p53/TP53, c-Jun/JUN)Transcriptional repressionRegulation of cell cycle and cellular homeostasis
03

Disease associations

CancerNeurodegenerative diseaseOther (Xeroderma pigmentosum, Moyamoya disease)
04

Safety considerations

Potential effects on ubiquitin pathway modulation, which may impact multiple cellular systems and homeostasisPossible broad tissue and pathway effects due to fundamental role in protein degradationNo direct therapeutic drugs or inhibitors currently established—targeting may risk toxicity/pleiotropy

Beyond the preview

Go deeper on COP9 signalosome complex subunit 1 (GPS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on COP9 signalosome complex subunit 1 (GPS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call